ArticleCancer medicine2026
A Multivariable Prediction Model for Early Mortality in Multiple Myeloma Patients With Renal Impairment.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite therapeutic advances, early mortality remains a significant challenge in multiple myeloma (MM) patients with renal impairment (RI), with no validated prognostic models currently available for this high-risk subgroup. This multicenter, retrospective study aimed to develop and validate a practical nomogram for predicting early death (< 12 months) using readily accessible clinical parameters. We analyzed data from 285 newly diagnosed MM patients with RI treated between 2007 and 2020, divided into training (n = 222) and validation (n = 63) cohorts. Multivariate analysis identified five independent predictors of early mortality: age > 55 years (OR 3.48, 95% CI 1.10-11.01), serum calcium ≥ 2.5 mmol/L (OR 3.29, 95% CI 1.30-8.29), bone marrow plasma cell percentage ≥ 40% (OR 2.90, 95% CI 1.24-6.77), renal response less than partial response (OR 0.27, 95% CI 0.11-0.65), and hematologic response less than complete response (OR 20.93, 95% CI 4.61-95.10). The developed nomogram demonstrated excellent discrimination (AUC 0.858) and calibration in the training cohort, with consistent performance in validation (AUC 0.747). Risk stratification categorized patients into three distinct prognostic groups with significantly different early mortality rates: Low Risk (1.6%), Mid Risk (13.9%), and High Risk (43.9%). This validated model provides the first practical tool for early mortality risk stratification in MM patients with RI, enabling clinicians to identify high-risk patients who may benefit from more intensive interventions. Further prospective validation is warranted to confirm generalizability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.